USA flag logo/image

An Official Website of the United States Government

NEW DRUG FOR PREVENTING POST-ISCHEMIC TISSUE INJURY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
11334
Program Year/Program:
1989 / SBIR
Agency Tracking Number:
11334
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Synergen Inc
1885 33rd St Boulder, CO 80301
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1989
Title: NEW DRUG FOR PREVENTING POST-ISCHEMIC TISSUE INJURY
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

NEUTROPHILS ARE A MAJOR CONTRIBUTOR TO THE CELLULAR DAMAGE THAT ACCOMPANIES REPERFUSION OF ISCHEMIC TISSUES. IT IS PLANNED TO CLONE AND PRODUCE THROUGH RECOMBINANT DNA METHODS A HUMAN PROTEIN THAT BLOCKS ATTACHMENT OF NEUTROPHILS TO ENDOTHELIAL CELLS IN VIVO AND THEREBY PREVENTS THE ENTRY OF NEUTROPHILS INTO REPERFUSED TISSUES AND THE CONSEQUENT ORGAN DAMAGE. THIS RESEARCH WILL ALSO LEAD TO THE DEVELOPMENT OF A NEW TECHNOLOGY FOR THE TREATMENT OF A LARGE CLASS OF HUMAN INFLAMMATORY DISEASES, SUCH AS ADULT RESPIRATORY DISTRESS SYNDROME, IRRITABLE BOWELDISEASE, AND IDIOPATHIC PULMONARY FIBROSIS, IN WHICH NEUTROPHILS APPEAR TO PLAY A DESTRUCTIVE ROLE. IN PHASE I, SYNERGEN, INC., WILL IMMUNIZE MICE AND SELECT FOR MONOCLONAL ANTIBODIES THAT REACT WITH THE PROTEIN, USINGAN IN VITRO FUNCTIONAL ASSAY. THESE MONOCLONALS WILL BE USED TO IDENTIFY THE PROTEIN ON WESTERN BLOTS AND IN IMMUNOPRECIPITATION EXPERIMENTS. IN PHASE II, THE MONOCLONAL ANTIBODIES WILL BE USED TO PURIFY ENOUGH OF THE PROTEIN TO DETERMINE A PARTIAL ANIMO ACID SEQUENCE. OLIGONUCLEOTIDES CORRESPONDING TO THE DETERMINED AMINO ACID SEQUENCE AND/OR THE MONOCLONAL ANTIBODIES WILL BE USED TO ISOLATE A CDNA ENCODING THE PROTEIN FROM A CDNA EXPRESSION LIBRARY. THE PROTEIN WILL BE PRODUCED IN LARGE QUANTITIES THROUGH RECOMBINANT DNA METHODS TO EVALUATE ITS EFFECTIVENESS IN VITRO AND IN VIVO FOR PREVENTING ATTACHMENT OF THE NEUTROPHILS TO ENDOTHELIAL CELLS AND CONSEQUENT DAMAGE TO REPERFUSED TISSUES.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Synergen Inc
1885 33rd St Boulder, CO 80301

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No